LEANGUARD®

A bioavailable combination of natural ingredients that addresses multiple targets in weight
management :

  • Supports Lean Body Mass and Healthy Body Composition
  • Promotes satiety
  • Provides Antioxidant support
Composition

Composition of LeanGard*:

  • ForsLean*
  • GarCitrin*
  • BioPerine*

Suggested Use level:
  • 500mg taken twice daily.

*Trademarks of Sabinsa Corporation
Synergy of Ingredients

ForsLean®

(Coleus forskohlii extract,10% forskolin):
Forskolin helps build
Lean body mass and maintain
healthy body composition
through cAMP mrdiated
action

GarCitrin®

(Garcinia cambogia Extract):
Hydroxycitric acid in
combination with
garcinol supports satiety
and weightloss through
citrase lyase inhibition
 

 

BioPerine®

(Piper nigrum Extract):
Enhances uptake and utilization of the
natural actives

 

 

 
ForsLean®
  • ForsLean® is a powdered extract from the root of Coleus forskohlii.
  • Standardized to contain 10% forskolin.
  • ForsLean®; is well-tolerated and without adverse side effects.
  • At 500mg/day for up to 12 weeks, produced no significant detrimental effects on biochemistry, hematological parameters, blood pressure or thyroid functions.
  • Expert Review Report from Cantox Health Sciences International ON, Canada, August 2004

www.forslean.com

The Coleus Root
Mechanism of Action
Clinical Studies on ForsLean®
  • Open field study (8 weeks) with 6 overweight women subjects – Dr. A. Conte, USA
  • Open-field study (6 months) with 16 obese subjects – Dr. Asano, Japan
  • Pilot clinical efficacy and safety study, 19 women subjects, randomized, double blind placebo controlled – University of Memphis TN, USA
  • Preclinical toxicology evaluation – CBPRC, Bombay
  • 60 subject clinical efficacy study – CBPRC, Bombay
  • 24 subject clinical efficacy study – Northern Michigan University, USA :: Double-blind placebo controlled study, 30 obese/overweight subjects – Kansas State University, USA
  • 60 subject clinical efficacy study– Manipal, India
  • 6 month feeding/toxicity study – India
  • Micronucleus assay and dose effects studies – India
  • Bone Density and Hormonal Levels Study, Mumbai, India
  • Hormonal Study (3months) with 30 male subjects, Manipal, India

ForsLean®
Won the Nutracon Best Product Award, 2001

US Patent # 5,804,596, won the Thomas Alva Edison Patent Award (R & D Council, NJ, USA) in 2004

ForsLean® is:
  • A safe, naturally derived, effective dietary ingredient composition
  • Patented* for use in promoting lean body mass
  • Clinically tested in humans (multiple studies)
  • Kosher & Halal Certified
  • A tried and tested ingredient that manufacturers,retailers and consumers can have confidence in
U.S. Patent # 5,804,596, European Patent # EP0977564, Canadian Patent # CA2281562

GarCitrin®

Source Garcinia cambogia
(Malabar tamarind, fam. Clusiaceae)
Plant part used Malabar tamarind, fam. Clusiaceae)
Active constituents (-) Hydroxycitric acid (HCA), Garcinol
Nutraceutical benefits Weight management support

U.S. Patent #7,063,861, Australia: AU773081, Europe: EP1254209, New Zealand: NZ 518116

GarCitrin®


Garcinol :

  • Amplifies the biological action of HCA
  • Contributes antioxidant activity to the formulation

The combination of calcium salt of HCA and Garcinol reduces fatty acid and lipid synthesis and improves
lean body mass much more effectively than HCA alone.

Clinical comparison between HCA and GarCitrin®

GarCitrin® is statistically more effective than HCA in:

  • Reducing total body weight and body mass index
  • Reducing body fat
  • Iincreasing lean body mass and content of body water
  • Reducing levels of appetite perception

GarCitrin® and HCA did not produce subjective or objective side effects.


BioPerine®

BioPerine® is a patented standardized extract obtained from black pepper, containing not less than 95% piperine.

A clinically proven natural bioavailability enhancer for nutrients.
Possible mechanisms for increased Nutrient bioavailability


Increases blood supply to the GI tract.

Increases emulsifying content of the gut.

Increases active nutrient transport.


BioPerine® is widely Patented
  1. U.S. Patent 5,536,506
  2. U.S. Patent 5,744,161
  3. U.S. Patent 5,972,3821
  4. U.S. Patent 6,054,585
  5. European Patent # EP0810868
  6. Japan Patent # 3953513
  7. Canada Patent # 2247467
www.bioperine.com
Study Design

controlled randomized double blind parallel-group study comparing the efficacy and safety.
Study Design
No. of volunteers 50 over-weight subjects in each group comprising of 24 Men and 26 Women ranging in age from 25 to 55 years.
Study duration 12 weeks.
Schedule of visits
Baselined Visit 1 Visit 2 Visit 3 Visit 4
Week 0 Week 3 Week 6 Week 9 Week 12
   

 
Dosage

500mg of the LeanGard® or Placebo was given twice daily to the participants of the trial.
Reduction in Body Weight
% Change in Waist : Hip Ratio
% Decrease in Body Mass Index
% Decrease in Body Fat
% Increase in Lean Body Mass
% Decrease in Basal Metabolic Rate


*Please note: The relationship between BMR and obesity is complex. BMR increases with obesity and overfeeding, a “coping mechanism” by the body. The results here indicate that LeanGard by supporting a healthy body composition, beneficially modulates increased BMR in obese/overweight subjects

% Decrease in Total Body Water

* Please Note: TBW: 4.66% average loss in Total Body Water from baseline corresponds to about 1.95 kg or about 4.29 lb. The actual average reduction in body fat corresponds to about 8.82 kg, or about 19.4 lb. Water forms roughly about 25% of the fat lost w/w, which corresponds to about 2.03 kg or 4.4 lb by weight. So essentially, the total body water lost can be related to water in the lost fat. Hence the intervention, LeanGard has no detrimental effects on hydration
Other Parameters

No significant changes in

  • Blood pressure or Heart rate
  • Hematological parameters
  • Liver function
  • Renal function
  • Thyroid function
  • Plasma lipid levels

  
Summary of Results
  Group 1 *
 (LeanGard)		 Group 2
 (Placebo)
Waist : Hip ratio 6.47% decrease. 1.89% increase.
Significant from V1 Significant in V2 & V3.
Basal Metabolic Index 7.45% decrease 1.09% decrease.
Significant from V1 Significant in V3 &V4.
Body Fat %
 8.15% decrease. 1.18% decrease.
Significant from V1 Significant in V3 & V4.

Lean Body Mass %

 4.36% Increase.
 0.67% Increase.
Significant from V1 Significant in V3 & V4.

Basal Metabolic Rate

 4.50% decrease. 0.64% decrease.
Significant from V1. Significant in V3 & V4.
Total Body Water

4.66% decrease.

 0.66% decrease.
Significant from V1. Significant in V3 & V4.

Significance at P< 0.05.
V1-visit 1, V2-visit 2, V3-visit 3, V4-visit 4.

Graphed Summary
Graphed Summary

Thank You

 
 
 
 
     
 
Copyright © 2007 Sabinsa Corporation All Rights Reserved